Using transcriptional profiling of a large collection of mPC tumor lesions and preclinical model systems, other investigators have found defined molecular subtypes of treatment resistance in metastatic tumor lesions, including tumors that retain strong activation of AR signaling, tumors with gene expression profiles of NEPC, an amphicrine subtype positive for both AR and NEPC markers, and double-negative PC (DNPC), which lack expression of either AR- or NEPC-specific transcripts. This evidence concerns the gene AR and neoplasm.